@ARTICLE{
author={Zemanova Milada,Jakopovic Marko,Stanic Karmen,Lazar-Poniatowska Malgorzata,Vrankar Martina,Rusu Petronela,Ciuleanu Tudor E,Radosavljevic Davorin Z,Bogos Krisztina,Nawrocki Sergiusz},
year={2020},
title={Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe},
journal={RADIOLOGY AND ONCOLOGY},
volume={54},
number={4},
pages={447-454},
document_type={Article},
} 

@ARTICLE{
author={Pillai Rathi N,Fennell Dean A,Kovcin Vladimir N,Ciuleanu Tudor E,Ramlau Rodryg,Kowalski Dariusz,Schenker Michael,Yalcin Ilker,Teofilovici Florentina,Vukovic Vojo M,Ramalingam Suresh S},
year={2020},
title={Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non?Small-Cell Lung Cancer (GALAXY-2)},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={38},
number={6},
pages={613-+},
document_type={Article},
} 

@ARTICLE{
author={Cufer Tanja,Ciuleanu Tudor E,Berzinec Peter,Galffy Gabriela,Jakopovic Marko,Jassem Jacek,Jovanovic Dragana D,Mihaylova Zhasmina,Ostoros Gyula,Thallinger Christiane,Zemanova Milada,Zielinski Christoph},
year={2020},
title={Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis},
journal={ONCOLOGIST},
volume={25},
number={3},
pages={E598-E601},
document_type={Article},
} 

@ARTICLE{
author={Pillai Rathi N,Fennell Dean,Kovcin Vladimir N,Ciuleanu Tudor E,Ramlau Rodryg,Kowalski Dariusz,Schenker Michael,Perin Branislav M,Yalcin Ilker,Teofilovici Florentina,Vukovic Vojo M,Ramalingam Suresh S},
year={2017},
title={Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2)},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={12},
number={1},
pages={S7-S8},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Brodowicz Thomas,Ciuleanu Tudor E,Radosavljevic Davorin Z,Shacham-Shmueli Einat,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank M,Purkalne Gunta,Messinger D,Zielinski Christoph},
year={2013},
title={FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study},
journal={ANNALS OF ONCOLOGY},
volume={24},
number={7},
pages={1769-1777},
document_type={Article},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shmueli E,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank M,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={29},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shmueli E,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Dank Magdolna,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={29},
number={4},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Nikolic Vladimir,Shacham-Shmueli Einat,Vrbanec Damir,Plate Signe,Mrsic-Krmpotic Zrinka,Kahan Zsuzsanna,Purkalne Gunta,Brodowicz Thomas,Zielinski Christoph},
year={2011},
title={Cetuximab Weekly (Q1W) Versus Every Two Weeks (Q2W) Plus Folfox4 as First-line Therapy in Patients (PTS) with Kras Wild-Type (WT) Metastatic Colorectal Cancer (MCRC)},
journal={ANNALS OF ONCOLOGY},
volume={22},
number={},
pages={v22-v22},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ciuleanu Tudor E,Samarzjia M,Demidchik Y,Beliakouski V,Rancic M,Bentsion DL,Orlov SV,Schaeffier BA,De Jager RL,Breitz HB},
year={2010},
title={Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={28},
number={15},
pages={-},
document_type={Meeting Abstract},
}